
Opinion|Videos|November 12, 2024
Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC
This episode addresses strategies for mitigating and managing adverse events associated with Dato-DXd in patients with advanced NSCLC, explores how the drug’s structure may help prevent acquired resistance mechanisms that are common with TKIs, and discusses the broader implications of integrating Dato-DXd and other ADCs into the treatment landscape for this patient population.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How would you mitigate or manage grade >3 Dato-DXd–related adverse events among your patients with advanced or metastatic NSCLC?
- How might the structure and function of Dato-DX-d deter the development of acquired resistance mechanisms observed with TKIs in this AGA population?
- How does the armamentarium expand here?
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

